Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Jay Luly Insider Profile
4 Followers
Jay Luly, President & CEO, Director at Enanta Pharmaceuticals, holds 810.61K shares in Enanta Pharmaceuticals (Ticker: ENTA).
Jay Luly Enanta Pharmaceuticals (ENTA)President & CEO, Director
Enanta Pharmaceuticals (ENTA)
President & CEO, Director
Ranked #72,324 out of 98,501 Corporate Insiders
Profitable Transactions
5 out of 11 Profitable Transactions
Average Return
-9.10%
Average return per transaction
Time Frame
Compare to
Insider Roles
President & CEO, Director
Roles that Jay Luly holds in companies
Most Profitable Insider Trade
Stock:
Rating:Informative Buy
Date:Jan 13, 2014 - Jan 13, 2015
Return:+53.90%
The most profitable trade made by Jay Luly
Jay Luly's Trading History
List of latest transactions for each holding click on a transaction to see Jay Luly's performance on stock
You May Also Like
Jay Luly insider profile FAQ
What is the percentage of profitable transactions made by Jay Luly?
The percentage of profitable transactions made by Jay Luly is 45%.
What is the average return per transaction made by Jay Luly?
The average return per transaction made by Jay Luly is -9.10%.
What stocks does Jay Luly hold?
Jay Luly holds: ENTA stocks.
What was Jay Luly’s latest transaction?
Jay Luly latest transaction was an Uninformative Buy of ―.
What was Jay Luly's most profitable transaction?
Jay Luly’s most profitable transaction was an Informative Buy of ENTA stock on January 13, 2014. The return on the trade was 53.90%.
What is Jay Luly's role in Enanta Pharmaceuticals?
Jay Luly's role in Enanta Pharmaceuticals is President & CEO, Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.